{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-031647","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.042523+00:00","generated_at":"2026-06-04T01:13:21.837305+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ImmuCell enters ATM offering agreement for up to $11M common stock with Craig-Hallum","bullets":["Company entered into ATM offering agreement with Craig-Hallum for up to $11M of common stock.","Craig-Hallum will receive 3.0% commission on gross proceeds from sales.","Company amended FAME loan agreement to remove restrictions on equity issuance.","Offering is under effective shelf registration statement (S-3) filed April 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-031647","json":"https://secwatch.observer/filing/0001213900-24-031647.json","markdown":"https://secwatch.observer/filing/0001213900-24-031647.md","text":"https://secwatch.observer/filing/0001213900-24-031647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390024031647/0001213900-24-031647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390024031647/ea0203573-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:13:21.837305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50441884a64ded581969b120c7d86a2c7e4a11b8","claim":"IMMUCELL CORP /DE/ amended First Amendment to Economic Recovery Loan Program Loan Agreement with Finance Authority of Maine valued at amends the FAME Loan Agreement to remove any restrictions on the Company’s ability to issue equity s (effective 2024-04-08).","evidence_excerpt":"In connection with entering into the Sales Agreement, on April 8, 2024, the Company entered into an amendment (the \"First Amendment\") to the Company's Economic Recovery Loan Program Loan Agreement, by and between the Company and the Finance Authority of Maine dated July 17, 2023 (the \"FAME Loan Agreement\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024031647/0001213900-24-031647-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Finance Authority of Maine"},{"label":"Value","value":"amends the FAME Loan Agreement to remove any restrictions on the Company’s ability to issue equity s"},{"label":"Effective","value":"2024-04-08"}],"fact_type":"material_agreement"},{"claim_id":"701dbe2770bd2b0e14234f429aa5b43f954c899a","claim":"IMMUCELL CORP /DE/ entered into At The Market Offering Agreement with Craig-Hallum Capital Group LLC valued at up to $11,000,000 of shares of common stock (effective 2024-04-09).","evidence_excerpt":"On April 9, 2024, ImmuCell Corporation (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, up to $11,000,000 of shares of its common stock, par value $0.10 per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024031647/0001213900-24-031647-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Craig-Hallum Capital Group LLC"},{"label":"Value","value":"up to $11,000,000 of shares of common stock"},{"label":"Effective","value":"2024-04-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}